Tonix Pharmaceuticals Holding Corp. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging -13.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-2.71 | $-2.44 | +10.0% | Beat | Q2 FY26 call |
| Q1 FY26 | $-2.38 | $-2.93 | -23.1% | Miss | |
| Q4 FY25 | $-3.16 | $-3.98 | -25.9% | Miss |
Back to TNXP overview · TNXP holders · TNXP KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.